Kostas Gavardinas is a Senior Principal Scientist at Eli Lilly and Company in the Lilly Genetic Medicine organization. He graduated from Illinois Wesleyan University in 1999 with a BS in Chemistry. During the summer of 1998, he joined Prof. Scott Denmark's lab at University of Illinois Champaign-Urbana as a Snyder scholar. Upon graduation from IWU, he joined Pfizer Central Research as a synthetic/medicinal chemist in the antibacterials department. In 2002, he moved to Eli Lilly as a medicinal chemist in the Discovery Chemistry Research & Technologies (DCRT) department, where he worked on a variety of endocrine/cardiovascular/oncology projects from early exploratory to clinical candidate selection stage. During that time, he developed a strong interest in computational/modeling methods and their application to drug discovery. In 2019, he joined the RNA computational group of the Lilly Genetic Medicine organization. In his current role, he is responsible for RNA design and synthesis, sequence selection, novel nucleoside chemistry, RNA molecular modeling, molecular dynamics simulations, RNA-related software development/integration with other Lilly systems and database administration.